Product Name | PMX 205 |
Product Quantity | 1 mg |
Catalog Number | LTC-001 |
Molecular Weight | 839.05 |
Formula | C45H62N10O6 |
Sequence | XPXWR (Modifications: X-1 = N2-(1-Oxo-3-phenylpropyl)-Orn, X-3 = D-Cha, Lactam bridge: Orn-1 to Arg-5) |
Purity | >95% |
CAS Number | 514814-49-4 |
Product Description | PMX 53 and PMX 205 are cyclic hexapeptide inhibitors of complement C5a receptors (C5aR1), that are widely used to study C5aR1 pathobiology in mouse models of disease. PMX 205 is a cyclic hexapeptide. It is a potent antagonist of C5a receptor (C5aR). It is orally active. PMX 205 is also brain penetrant and reduces fibrillar amyloid deposits, decreases hyperphosphorylated tau levels and rescues cognitive function. PMX205 entered the intact CNS at pharmacologically active concentrations, with increased entry observed in hSOD1G93A mice. |
Scientific Background | PMX 205 is a 6-residue synthetic peptide with the sequence Leu-Ala-Cys-Thr-Ala-Met. The sequence contains 1 cysteine residue, providing potential thiol/disulfide chemistry when the thiol is available; has a relatively high hydrophobic-residue fraction that can influence aqueous solubility and surface adsorption. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence. |
Research Applications | - thiol-selective conjugation or immobilization studies
- LC-MS/HPLC analytical method development
- sequence-specific assay controls
|
Experimental Notes | Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions. |
